Datapoint: Supreme Court Ends Repatha-Praluent Patent Saga

The United States Supreme Court on May 18 ended a long-running patent dispute between Amgen, Sanofi and Regeneron over the drugmakers’ PCSK9 inhibitors. Justices upheld a 2019 lower court ruling, which stated that Amgen could not make patent claims over monoclonal antibodies without more thoroughly describing their molecular structure, a decision that could have wider implications for the pharmaceutical industry as a whole. Praluent and Repatha are both approved to treat three forms of high low-density lipoprotein cholesterol (LDL-C); heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD), and homozygous familial hypercholesterolemia (HoFH). Under the pharmacy benefit, Repatha SureClick holds covered or better status for 82% of all insured lives, to Praluent Pen’s 71%.

SOURCE: MMIT Analytics, as of 5/22/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 24

Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 23

Datapoint: Elevance to Take On Primary Care Expansion

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 18

Datapoint: FDA Delays New Leqembi Launch

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today